Dr. Shakti Singh

Shakti Singh, PhD, MS

Investigator, The Lundquist Institute
Assistant Professor, David Geffen School of Medicine, University of California, Los Angeles
Infectious Disease Faculty member at Harbor-UCLA Medical Center

Microbial pathogenesis and vaccine/immunotherapeutic development

Research Description

Candida auris pathogenesis and vaccine /immunotherapeutic development

Candida auris has emerged as a major threat to the health of immunosuppressed patients with indwelling catheters, shunts, and other invasive medical devices. High mortality rate (~60%), resistance to virtually all major classes of drugs and propensity to spread and cause outbreaks in healthcare settings around the globe, forced the Center for Disease Control and Prevention (CDC) to declare Candida auris as “Serious Threat Level” pathogen. Moreover, the virulence and pathogenic mechanisms of C. auris in its host is virtually unknown. Considering the multi-drug resistance (MDR) profile and high mortality rate, alternative vaccine and immunotherapeutic strategies are the most promising approaches to control C. auris infections.

Dr. Singh identified orthologs of an Aggultinin-like protein (a Candida albicans protein antigen CA-Als3p) on Candida auris and showed that a CA-Als3p containing NDV-3A vaccine (developed by the Investigators at the Lundquist) partially protected mice from this “new superbug”. We hypothesize that a vaccine derived from C. auris will likely be more protective against this MDR pathogen. My current research involved the characterization of C. auris cell surface proteins and their potential role in virulence and pathogenesis. The goal of this research is to identify potential targets for vaccine and immunotherapeutic development using cutting edge vaccine technologies such as novel adjuvants and mRNA-based platforms.
Theme Groups
Research Interests


  • BS, Chaudhary Charan Singh University, Meerut, UP, India
  • MS, Chaudhary Charan Singh University, Meerut, UP, India
  • PhD, University of Alberta, AB, Canada

Recent and/or Significant Publications

Singh S, Vedi S, Li W, Samrat SK, Kumar R, Agrawal B. Recombinant adenoviral vector expressing HCV NS4 induce protective immune responses in a mouse model of Vaccinia-HCV virus infection: A dose and route conundrum. Vaccine. 2014 May 13;32(23):2712-21. PMID: 24631092
Singh S, Vedi S, Samrat SK, Li W, Kumar R, and Agrawal B. Heterologous Immunity Between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines. PLoS One. 2016 Jan 11; 11(1): e0146404. PMID: 26751211
Singh S, Ramirez E, Doueiri R, Valentin A, Rosati M, Hu X, Keele BF, Shen X, Tomaras GD, Ferrari G, LaBranche C, Montefiori DC, Das J, Alter G, Trinh HV, Hamlin C, Rao M, Dayton F, Bear J, Chowdhury B, Alicea C, Lifson JD, Broderick KE, Sardesai NY, Sivananthan SJ, Fox CB, Reed SG, Venzon DJ, Hirsch VM, Pavlakis GN, Felber BK. DNA and protein co-immunization regimens combined with different Toll-like receptor-4 (TLR-4) based adjuvants induce immune responses controlling SIVsmE660 infection. Journal of Virology, 2018 Jul 17; 92(15). PMID: 29793957
Uppuluri P, Singh S, Alqarihi A, Alqarihi A, Schmidt CS, Hennessey JP, Yeaman MR, Filler SG, Edwards JE, and Ibrahim AS. Human Als3p Antibodies are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. Frontiers in Immunology, 2018 Jun 15; 9:1349. PMID: 29963049
Alqarihi A, Singh S, Edwards Jr JE, Ibrahim AS, Uppuluri P. NDV-3A vaccination prevents C. albicans colonization of jugular vein catheters in mice Nature Scientific Report. 2019 Apr 17;9(1):6194. PMID: 30996274
Singh S, Uppuluri P, Mamouei Z, Alqarihi A, Elhassan H, French S, Lockhart SR, Chiller T, Edwards Jr JE, Ibrahim AS. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. PLoS Pathogens. 2019 Aug 5; 15(8): e1007460. PMID: 31381597
Iyer KA, Camara K, Daniel-Ivadd M, Trilles R, Pimentel-Elardod SM, Fossen JL, Marchillo K, Liu Z, Singh S, Muñoz JF, Kim SH, Porco JA Jr, Cuomo CA, Williams NS, Ibrahim AS, Edwards JE Jr, Andes DR, Nodwell JR, Brown LE, Whitesell L, Robbins N, Cowen LE. Novel 3,3-diarylated oxindole efflux inhibitor provides a promising approach to combat azole resistance in the emerging fungal pathogen Candida auris. Nature Communications. 2020 Dec 22; 11, 6429. PMID: 33353950
Soliman SSM, Baldin C, Gu Y, Singh S, Gebremariam T, Swidergall M, Alqarihi A, Youssef EG, Alkhazraji S, Pikoulas A, Perske C, Venkataramani V, Rich A, Bruno VM, Hotopp JD, Mantis NJ, Edwards JE Jr, Filler SG, Chamilos G, Vitetta ES, Ibrahim AS. Mucoricin is a Ricin-Like Toxin that is Critical for the Pathogenesis of Mucormycosis. Nature Microbiology. 2021 Jan 18. PMID: 33462434
Ost K, O’ Meara TR, Stephens WZ, Chiaro T, Zhou H, Penman J, Bell R, Catanzaro JR, Song D, Singh S, Call DH, Hwang-Wong E, Hanson KE, Valentine JF, Christensen KA, O’Connell RM, Cormack B, Ibrahim AI, Palm NW, Noble SM & Round JL. Adaptive immunity promotes a mutually beneficial interaction between commensal eukaryotes. Nature. 2021 July 14, 596, pages114–118. PMID: 34262174
Mamouei Z, Singh S, Lemire B, Gu Y, Alqarihi A, Nabeela S, Li D, Ibrahim AS, Uppuluri P. An evolutionarily diverged mitochondrial protein controls biofilm growth and virulence in Candida albicans. PloS Biology. 2021 Mar 15;19(3):e3000957. PMID: 33720927
Singh S, Nabeela S, Barbarino A, Ibrahim AS, Uppuluri P. Antibodies targeting Candida albicans Als3 and Hyr1 antigens protect neonatal mice from candidiasis. Frontiers in Immunology. 2022 Jul 22; 13:925821